Literature DB >> 10749316

Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria.

K Hultén1, A Almashhrawi, F A El-Zaatari, D Y Graham.   

Abstract

The most commonly used antibiotics in Crohn's disease are nitroimidazoles and macrolides often combined with corticosteroids or sulfasalazine. There has been interest in a mycobacterial involvement in Crohn's disease since its earliest description. It is not recognized that Mycobacterium avium subspecies paratuberculosis, a proven but uncommon cause of human disease, is widespread in the human food chain especially in dairy products and beef. M. paratuberculosis has been identified in tissues from a higher proportion of Crohn's disease patients than controls, suggesting that it may be one of the causes of Crohn's disease. We review the large number of antibiotic trials in Crohn's disease. Although studies have been performed with many different protocols and variations in the definition of success, preliminary reports of multiple drug therapies are encouraging. Nevertheless, large-well designed preferably placebo-controlled studies are needed before one could recommend such therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749316     DOI: 10.1023/a:1005453409445

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  45 in total

1.  Ethambutol in tuberculosis.

Authors:  L M Kahana
Journal:  Biomed Pharmacother       Date:  1990       Impact factor: 6.529

2.  Development of a firefly luciferase-based assay for determining antimicrobial susceptibility of Mycobacterium avium subsp. paratuberculosis.

Authors:  S L Williams; N B Harris; R G Barletta
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

Review 3.  Mycobacterium paratuberculosis cervical lymphadenitis, followed five years later by terminal ileitis similar to Crohn's disease.

Authors:  J Hermon-Taylor; N Barnes; C Clarke; C Finlayson
Journal:  BMJ       Date:  1998-02-07

4.  Antimycobacterial therapy ineffective in Crohn's disease after a year.

Authors:  G Järnerot; P Rolny; G Wickbom; G Alemayehu
Journal:  Lancet       Date:  1989-01-21       Impact factor: 79.321

Review 5.  Crohn's disease and mycobacteria: two cases of Crohn's disease with high anti-mycobacterial antibody levels cured by dapsone therapy.

Authors:  C Prantera; G Bothamley; S Levenstein; R Mangiarotti; R Argentieri
Journal:  Biomed Pharmacother       Date:  1989       Impact factor: 6.529

6.  [The course of Crohn disease and side effect profile with long-term treatment using metronidazole].

Authors:  R Gugler; J C Jensen; H Schulte; R Vogel
Journal:  Z Gastroenterol       Date:  1989-11       Impact factor: 2.000

7.  Metronidazole in Crohn's disease. A double blind cross-over clinical trial.

Authors:  P Blichfeldt; J P Blomhoff; E Myhre; E Gjone
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

8.  Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen.

Authors:  C Prantera; A Kohn; R Mangiarotti; A Andreoli; C Luzi
Journal:  Am J Gastroenterol       Date:  1994-04       Impact factor: 10.864

9.  Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.

Authors:  E Langholz; J Brynskov; K Bendtzen; M Vilien; V Binder
Journal:  Aliment Pharmacol Ther       Date:  1992-08       Impact factor: 8.171

10.  Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol.

Authors:  N Rastogi; K S Goh; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more
  7 in total

Review 1.  Antibiotics in Crohn's disease.

Authors:  J F Colombel; A Cortot; H J van Kruiningen
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 2.  Mycobacterium paratuberculosis as a cause of Crohn's disease.

Authors:  Adrienne L McNees; Diane Markesich; Najah R Zayyani; David Y Graham
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-10-16       Impact factor: 3.869

3.  [Severe ileocolitis refractory to standard medical treatment. A diagnostic dilemma].

Authors:  A Hofer; S Schmiedel; A W Lohse; G D Burchard
Journal:  Internist (Berl)       Date:  2008-09       Impact factor: 0.743

Review 4.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.

Authors:  W Kruis; P Fric; J Pokrotnieks; M Lukás; B Fixa; M Kascák; M A Kamm; J Weismueller; C Beglinger; M Stolte; C Wolff; J Schulze
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

Review 6.  Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility.

Authors:  Franco Scaldaferri; Viviana Gerardi; Loris Riccardo Lopetuso; Fabio Del Zompo; Francesca Mangiola; Ivo Boškoski; Giovanni Bruno; Valentina Petito; Lucrezia Laterza; Giovanni Cammarota; Eleonora Gaetani; Alessandro Sgambato; Antonio Gasbarrini
Journal:  Biomed Res Int       Date:  2013-08-07       Impact factor: 3.411

7.  Effects of monocolonization with Escherichia coli strains O6K13 and Nissle 1917 on the development of experimentally induced acute and chronic intestinal inflammation in germ-free immunocompetent and immunodeficient mice.

Authors:  T Hudcovic; R Stepánková; H Kozákova; T Hrncír; H Tlaskalová-Hogenová
Journal:  Folia Microbiol (Praha)       Date:  2007       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.